HA 14-1 is a small-molecule Bcl-2 antagonist that promotes apoptosis in malignant cells, but its mechanism of action is not well defined. We recently reported that
HA 14-1 has a half-life of only 15 min in vitro, which led us to develop a stable analog of
HA 14-1 (sHA 14-1). The current study characterizes its mode of action. Because of the antiapoptotic function of Bcl-2 family
proteins on the endoplasmic reticulum (ER) and mitochondria, the effect of
sHA 14-1 on both organelles was evaluated.
sHA 14-1 induced ER
calcium release in human leukemic cells within 1 min, followed by induction of the ER stress-inducible
transcription factor ATF4. Similar kinetics and stronger intensity of ER
calcium release were induced by the sarcoendoplasmic reticulum Ca(2+)-
ATPase (SERCA) inhibitor
thapsigargin, accompanied by similar kinetics and intensity of ATF4 induction.
sHA 14-1 directly inhibited SERCA enzymatic activity but had no effect on the
inositol triphosphate receptor. Evaluation of the mitochondrial pathway showed that
sHA 14-1 triggered a loss of mitochondrial transmembrane potential (Delta psi m) and weak
caspase-9 activation, whereas
thapsigargin had no effect. (R)-4-(3-Dimethylamino-1-phenylsulfanylmethyl-propylamino)-N-{4-[4-(4'-chloro-
biphenyl-2-ylmethyl)-piperazin-1-yl]-benzoyl}-3-nitrobenzenesulfonamide (ABT-737), a well established small-molecule Bcl-2 antagonist, rapidly induced loss of Delta psi m and
caspase-9 activation but had no effect on the ER. The pan-
caspase inhibitor N-
benzyloxycarbonyl-Val-Ala-Asp-fluoromethyl
ketone had some protective effect on sHA 14-1-induced cell death. These collective results suggest a unique dual targeting mechanism of
sHA 14-1 on the apoptotic resistance machinery of
tumor cells that includes antiapoptotic Bcl-2 family
proteins and SERCA
proteins.